DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.04
+2.44%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 28.27x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.45x
- Price / sales
- 800.12x
- Price / cash flow
- -6.64x
Enterprise value
- Enterprise value
- $2.2B
- EV / sales
- 610.62x
- EV / EBITDA
- -4.42x
- EV / EBIT
- -4.06x
- Market cap
- $2.9B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026